Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus - associated hepatocellular carcinoma. by Melis M et al.
Melis et al. Journal of Translational Medicine 2014, 12:230
http://www.translational-medicine.com/content/12/1/230RESEARCH Open AccessViral expression and molecular profiling in liver
tissue versus microdissected hepatocytes in
hepatitis B virus - associated hepatocellular
carcinoma
Marta Melis1, Giacomo Diaz2, David E Kleiner3, Fausto Zamboni4, Juraj Kabat5, Jinping Lai3, Giulia Mogavero4,
Ashley Tice1, Ronald E Engle1, Steven Becker5, Charles R Brown6, Jeffrey C Hanson7, Jaime Rodriguez-Canales7,
Michael Emmert-Buck7, Sugantha Govindarajan8, Michael Kew9 and Patrizia Farci1*Abstract
Background: The molecular mechanisms whereby hepatitis B virus (HBV) induces hepatocellular carcinoma (HCC)
remain elusive. We used genomic and molecular techniques to investigate host-virus interactions by studying multiple
areas of the same liver from patients with HCC.
Methods: We compared the gene signature of whole liver tissue (WLT) versus laser capture-microdissected (LCM)
hepatocytes along with the intrahepatic expression of HBV. Gene expression profiling was performed on up to 17
WLT specimens obtained at various distances from the tumor center from individual livers of 11 patients with HCC and
on selected LCM samples. HBV markers in liver and serum were determined by real-time polymerase chain reaction (PCR)
and confocal immunofluorescence.
Results: Analysis of 5 areas of the liver showed a sharp change in gene expression between the immediate perilesional
area and tumor periphery that correlated with a significant decrease in the intrahepatic expression of HB surface antigen
(HBsAg). The tumor was characterized by a large preponderance of down-regulated genes, mostly involved in the
metabolism of lipids and fatty acids, glucose, amino acids and drugs, with down-regulation of pathways involved
in the activation of PXR/RXR and PPARα/RXRα nuclear receptors, comprising PGC-1α and FOXO1, two key regulators
critically involved not only in the metabolic functions of the liver but also in the life cycle of HBV, acting as essential
transcription factors for viral gene expression. These findings were confirmed by gene expression of microdissected
hepatocytes. Moreover, LCM of malignant hepatocytes also revealed up-regulation of unique genes associated with
cancer and signaling pathways, including two novel HCC-associated cancer testis antigen genes, NUF2 and TTK.
Conclusions: Integrated gene expression profiling of whole liver tissue with that of microdissected hepatocytes
demonstrated that HBV-associated HCC is characterized by a metabolism switch-off and by a significant reduction in
HBsAg. LCM proved to be a critical tool to validate gene signatures associated with HCC and to identify genes that
may play a role in hepatocarcinogenesis, opening new perspectives for the discovery of novel diagnostic markers and
therapeutic targets.
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Hepatocellular carcinoma (HCC) is the third leading cause
of cancer-related death worldwide [1]. In most patients,
HCC arises in the setting of chronic liver disease of vari-
ous etiologies, with cirrhosis being present in about 80%
of the cases [2]. Chronic infection with hepatitis B virus
(HBV) and hepatitis C virus (HCV) is responsible for over
80% of HCC cases worldwide. HBV was one of the first
viruses for which a direct link with the development of
HCC was demonstrated [3,4]. Thus, HCC was the first
human cancer for which a viral cause was established,
and the first to be shown to be preventable by universal
vaccination [5]. Although the availability of an effective
vaccine against HBV promises the eventual elimination
of HBV-associated HCC, more than 350 million chronic
carriers of HBV in the world are still at increased risk of
developing cirrhosis and HCC, making HBV, along with
tobacco, the most important environmental carcinogen
[6]. Although the causal association between HBV and
HCC has been well established, the molecular mecha-
nisms of hepatocarcinogenesis remain elusive.
The advent of post-genomic technologies has provided
tools to investigate the pathogenesis of liver cancer, making
study of the simultaneous expression of mRNA of thou-
sands of genes in a single array possible [7]. However, many
studies of HCC derived from gene expression profiling have
focused mainly on the host and little on the virus. HCC pa-
tients are often analyzed as a single group regardless of the
etiologic factor involved, and the clinical, virologic and
histologic features studied are often limited or missing.
Moreover, there is limited information on the gene expres-
sion profiles of the surrounding non-tumorous tissue [8,9].
We took advantage of a unique collection of liver
specimens from patients who underwent orthotopic liver
transplantation (OLT) or partial hepatectomy for HBV-
associated HCC to study simultaneously host and viral
factors that contribute to hepatocarcinogenesis. To the
best of our knowledge, this is the first study that reports
the results of an extensive microarray analysis in which
up to 17 specimens per patient were analyzed, including
samples from the tumor, the neighboring tissue, and the
most distant non-tumorous tissues, along with the intra-
hepatic expression of HBV. Moreover, because the liver
contains heterogeneous cell populations, we investigated
the gene expression profiles of malignant versus non-
malignant hepatocytes isolated by laser capture micro-
dissection (LCM). The combined study of gene expression
profiling of whole liver tissue (WLT) with malignant and
non-malignant microdissected hepatocytes, along with the
analysis of the intrahepatic expression and distribution of
HBV, provided new insights into the molecular programs
involved in the pathogenesis of HBV-associated HCC,
opening new perspectives for the identification of novel
tumor markers, which are needed for the early detectionof HCC and for the development of novel forms of
therapy.
Methods
Patients
Multiple liver specimens were obtained from a cohort of
11 patients who underwent OLT or partial hepatectomy
for HBV-associated HCC between 2004 and 2008 at the
Liver Transplantation Center of the Brotzu Hospital in
Cagliari, Italy. The patient characteristics are described
in the Results section. The study was approved by the
Office of Human Subjects Research of the National In-
stitutes of Health, granted on the condition that all
samples be made anonymous.
Liver pathology
Liver biopsies were evaluated blindly by two expert
hepatopathologists (D.K. and S.G.). For each liver biopsy
specimen, activity grade and stage of fibrosis were estab-
lished according to Ishak scoring system [10]. The grade
of tumor differentiation was evaluated according to the
Edmondson and Steiner grading system [11]. The HCC
subtype was defined according to the classification of
Yamashita et al. [12] based on EpCAM and alpha-
fetoprotein (AFP) expression.
Design of the study
Whole liver tissue
Because of the complexity of HCC, our initial approach
was to investigate, by microarray, the molecular heterogen-
eity within and outside the tumor by mapping the entire
liver containing HCC. For this purpose, we analyzed up to
17 liver specimens for each of the 11 patients, taken in all
4 directions, termed north (N), south (S), east (E), and west
(W) for simplicity, starting from the center of the tumor
(Figure 1A). Specifically, the design included 5 biopsies
from the tumor, one at the center (A) and 4 in the periph-
ery of the tumor (B: N, S, E and W); 4 biopsies from
the perilesional area (C: N, S, E and W); 4 biopsies
taken 2-3 cm from the tumor (D: N, S, E and W); and 4
biopsies from the edges of the liver (E: N, S, E and W).
In some cases, however, collection of non-tumorous
liver specimens at all distances and directions from the
center of the tumor was not possible because of the loca-
tion of the tumor. On average, 11 liver specimens were
collected from each patient from a total of 120 liver sam-
ples (39 from the tumor and 81 from the non-tumorous
tissue) from the 11 patients. Each sample was divided into
two pieces: one was snap-frozen for molecular studies and
the other was formalin-fixed and paraffin-embedded
(FFPE) for pathological examination. Importantly, when
FFPE sections obtained from the tumor or the perilesional
area showed a mixed population of tumor and non-tumor
hepatocytes, the corresponding frozen liver specimens
Figure 1 Schematic representation of the study design illustrating
the liver specimens analyzed for gene expression profiling and the
multidimensional scaling plot. (A) Different colors represent samples
collected at different distances from HCC in the four directions
(North, South, East and West). Red: HCC center (A area). Orange:
HCC periphery (B area). Green: perilesional, non-tumorous tissue (C area).
Turquoise: 2-3 cm from HCC (D area). Indigo: edge of the liver, 6-10 cm
from HCC (E area). (B) Gene expression profiling of HBV-associated HCC.
Multidimensional scaling plot showing the 3D projection of 120
liver specimens obtained at different distances from HCC from 11
patients. Each point of the scatterplot represents a liver specimen,
and the distance between points is proportional to the overall
dissimilarity of gene expression profiles.
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specimens analyzed, only two were excluded for the pres-
ence of a mixed population.
Laser capture microdissection
Because the liver contains a heterogeneous cell popula-
tion, we also performed gene expression profiling on
malignant and non-malignant hepatocytes, isolated by
LCM, in 10 of the 11 patients previously investigated by
microarray using WLT. For each patient, one biopsy
from the center of the tumor (A) and one from the mostdistant area (E) were selected for LCM. We optimized
the LCM method based on the procedure previously
published by Erickson et al. [13]. Frozen liver sections
were cut to a thickness of 8 μm and mounted on PEN
membrane frame slides (Life Technologies, Carlsbad,
CA, USA). Serial frozen sections were formalin fixed,
H&E stained, and evaluated by a pathologist to deter-
mine areas of interest before dissection. To preserve
RNA integrity, H&E staining was performed on ice and
optimized for tissue visualization. Briefly, the excess of
OCT was removed by submerging the slides in 70%
ethanol (30 seconds), followed by molecular grade water
(20 seconds), hematoxylin (30 seconds), molecular grade
water (20 seconds), 1× bluing solution (20 seconds), 70%
ethanol (30 seconds), eosin (3 seconds), 95% ethanol
(30 seconds twice), 100% ethanol (30 seconds twice),
and finally xylene (30 seconds). Xylene was allowed to
completely evaporate from the slides in a chemical hood
before use. LCM was performed using the Arcturus
XTTM Microdissection System (Life Technologies, Carlsbad,
CA, USA). Areas of interest identified by a trained path-
ologist were selected on the freshly stained PEN membrane
sections prior to placing the cap on the tissue. After cap
placement, an infrared laser was used to melt the cap poly-
mers to the areas of interest and a UV laser was used to cut
these areas (Additional file 1: Figure S1). The cell popula-
tions were collected on the cap, removed from the PEN
membrane slide, and incubated in the lysis buffer. RNA
extraction was completed using the Arcturus PicoPure
RNA Isolation Kit (Life Technologies, Carlsbad, CA,
USA) according to the manufacturer’s recommendations.
Approximately 2-7 square millimeters of tissue was cut
from the section. The cell population recovered depended
on the amount of artifact present, the cellular density and
the size of the tissue section. In some cases, cells were col-
lected from multiple sequential tissue slides. In order to
minimize degradation of RNA from microdissected cells,
LCM was completed within 60 minutes after staining and
the RNA quality and integrity were assessed.
Gene expression profiling
All liver specimens were analyzed by microarray using
Affymetrix Human U133 Plus 2.0 arrays, which contain
54,675 transcripts representing approximately 27,000
unique human genes. Total RNA from WLT was extracted
from frozen liver specimens as previously described [14]
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s recommendations;
total RNA from microdissected hepatocytes was ex-
tracted using the Arcturus PicoPure RNA Isolation Kit
(Life Technologies, Carlsbad, CA, USA). The specimens
used for RNA extraction and LCM were derived from the
same frozen liver samples. Total RNA quality and integrity
were assessed using the Agilent 2100 Bioanalyzer (Santa
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LCM and WLT, gene expression profiling was performed
using the same technique as previously reported [14].
Total liver RNA (50 ng) obtained from whole liver tissue
and microdissected hepatocytes was subjected to two suc-
cessive rounds of amplification [15], and the resultant
RNA was then subjected to biotin labeling, hybridization,
staining, washing, and scanning procedures according to
standard Affymetrix protocols.Serological and virological assays
Serologic markers of infection with hepatitis viruses were
available in all patients at the time of OLT or partial hepa-
tectomy. HBsAg, anti-HBs, anti-HBc, IgM anti-HBc,
HBeAg, anti-HBe, antibody to HCV (anti-HCV), and anti-
body to human immunodeficiency virus (anti-HIV) were
measured with a commercial enzyme immunoassay
(Abbott Laboratories, North Chicago, IL, USA). Anti-
bodies against hepatitis delta antigen (HDAg), IgG and
IgM anti-HD, were measured using commercial enzyme
immunoassays (Sorin Biomedica, Saluggia, Italy). Serum
HBV DNA was quantified by a commercial assay
(Amplicor, HBV Monitor test; Roche Diagnostics,
Branchburg, NJ, USA). Serum HCV RNA was mea-
sured by a commercial assay (Cobas Amplicor HCV
Monitor 2.0, Roche Diagnostics). Serum HDV RNA
was evaluated by PCR as previously reported [16].Real-time polymerase chain reaction (PCR) assay for liver
HBV DNA
HBV DNA in liver was quantified using a modification
of a previously described method [17]. Briefly, 50 ng of
total liver DNA were tested by real-time PCR. The
primers/probe were located near the 5′ end of the S
gene. Each 20 μL reaction contained 45 pmol of forward
(5′- GGA CCC CTG CTC GTG TTA CA-3′) and
reverse (3′- TTG AGA GAA GTC CAC CAC GAG TC-
5′) primers, 12.5 pmol of non-fluorogenic-quenched-
probe (6FAM- TGT TGA CAA GAA TCC TCA) and
TaqMan® Fast Universal PCR Master Mix (Applied Bio-
systems, Foster City, CA). PCR was performed using an
ABI PRISM® 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA). Conditions included incuba-
tion at 95°C for 20 seconds followed by 45 PCR cycles of
1 second at 95°C and 20 seconds at 60°C. Viral titers were
expressed as log10 IU per mL. The Acrometrix Optiquant
(Acrometrix, Benicia, CA) HBV viral DNA panel was used
to construct a standard curve from which IU quantities
were determined. It consisted of 6 samples containing
2×102 to 2×107 IU/mL of HBV plus a negative control. The
quantities of HBV DNA were calibrated using the WHO
international standards (97/746), as previously described by
Saldanha et al [18].Real-time quantitative PCR to validate cancer testis
antigens identified by gene expression profiling
Real time reverse transcriptase quantitative polymerase
chain reaction (RT QPCR) was used to validate four can-
cer testis antigens (CTA) found to be differentially
expressed in microdissected hepatocytes between tumor
and non-tumorous tissue. We used total RNA obtained
from whole liver tissue because total RNA from microdis-
sected hepatocytes had been entirely used for gene expres-
sion profiling. Reverse transcription was performed with a
Bio-Rad iScript cDNA Synthesis Kit (Bio-Rad, Hercules,
CA) and 25 ng of cDNA was used for each target in the
SYBR Green QPCR method. We used commercially avail-
able primers for all four targets, as well as for the refer-
ence housekeeping gene (GAPDH) (PrimePCR, Bio-Rad,
Hercules, CA). Reaction mixtures included SsoAdvanced
Universal SYBR Green Supermix (Bio-Rad), target primer
mix and samples, all used at the manufacturer’s recom-
mended concentrations. PCR was carried out using an ABI
PRISM® 7900HT Sequence Detection System (Applied Bio-
systems, Foster City, CA). Cycling conditions included
2 minutes at 95°C followed by 40 cycles of 5 seconds
denaturation at 95°C, and 30 seconds annealing/exten-
sion at 60°C. Samples were tested in triplicate and the
average results were expressed as –ΔΔCt [19], where
ΔΔCt = (CtTarget - CtGAPDH )Tumor - (CtTarget -
CtGAPDH)Non-Tumor.
Immunohistochemistry, immunofluorescence, confocal
microscopy, and image analysis
To define the HCC subtype, we investigated the expres-
sion of EPCAM and AFP in tumor liver sections [12].
Immunohistochemical staining of formalin fixed paraffin-
embedded liver sections was performed using antibodies
against EPCAM (Dako M0804, 1:200) and AFP (Dako
A008, 1:2500). A BenchMark XT autostainer was used for
antigen retrieval (if necessary), primary and secondary
antibody incubation and detection according to the manu-
facturer’s instructions. Immunohistochemical staining of
EPCAM was performed after antigen retrieval using treat-
ment with Protease 1 (Ventana) for 4 minutes. Detection
of AFP did not require antigen retrieval. To investigate
the expression of the HBV markers, HBsAg and HBcAg,
throughout the entire liver, we performed immunofluores-
cence and confocal microscopy in 10 of the 11 patients
previously analyzed by microarray. We analyzed 4 liver
specimens for each patient including two from the tumor
(A and B) and 2 from the non-tumorous tissue, including
the perilesional area (C) and the most distant non-
tumorous tissue (E), along a single direction. Thus, a total
of 20 tumor and 20 non-tumorous tissues were examined
by immunofluorescence. As a negative control, we used
FFPE liver sections obtained from a liver donor who
showed normal liver histology and was negative for
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intrahepatic HBsAg and HBcAg, we used the method re-
ported by Mensa et al. with some modifications [20]. Rep-
resentative FFPE sections of 3 to 5 μm were heated
overnight at 37°C, subsequently deparaffinized by xylene,
and rehydrated in successive graded alcohol to distilled
water. Antigen retrieval was performed with a pressure
cooker (Dako, Glostrup, Denmark) by submerging sec-
tions in DIVA Decloaker Solution (Biocare Medical, LLC,
Concord, CA, USA); the sections were then heated at
125°C at 21 psi for 4 minutes and 30 seconds. Non-
specific binding sites were blocked with 10% goat
serum for 30 minutes, and then slides were stained with
mouse monoclonal anti-HBsAg (Dako) or rabbit poly-
clonal anti-HBcAg (Dako) for 1 hour at room temperature.
After rinsing with 1× phosphate buffered saline (PBS), sec-
tions were incubated with a 1:400 dilution of the corre-
sponding secondary antibody, Alexa Fluor 568 F(ab’) 2
fragment of goat anti-mouse IgG or Alexa Fluor 488 goat
anti-rabbit IgG (both from Invitrogen, Carlsbad, CA, USA)
for 30 minutes. After 3 washes with 1× PBS, samples were
stained with DAPI (Invitrogen) and mounted with Fluores-
cence Mounting Medium (Dako). Samples were kept
overnight in the dark before observation with a con-
focal microscope. Images were obtained using a Leica
SP5 (Leica Microsystems, Exton, PA, USA) equipped
with the 63× oil immersion objective NA 1.4. DAPI was
excited using a 364 nm Enterprise II UV laser (Coherent,
Santa Clara, CA, USA). To avoid emission crosstalk, se-
quential frame averaged scans were set up for each fluoro-
phore. Data were deconvolved with Huygens Essential
software (version 4.2.1p4, Scientific Volume Imaging BV,
Hilversum, Netherlands). Sequential Z-sections of stained
cells were acquired for 3-D reconstruction and iso-surface
modeling with Imaris software (version 7.5.1, Bitplane
AG, Zurich, Switzerland). The number of negative and
positive cells was determined using the spot, surface and
masking function of Imaris, and statistical data were cal-
culated from multiple samples (at least 4 images for sec-
tion) for each experiment.
Statistical analysis
Microarray data were analyzed using BRB-Array Tools
Version 4.2 [21], as previously reported [14]. Briefly,
microarray raw data (.CEL files) were summarized and
normalized by the RMA method. Transcripts showing
minimal variation (less than 1.5-fold deviations from the
median in more than 80% of the arrays) were excluded
from the analysis. After filtering, only 21% of transcripts
(11,377 from WLT and 11,224 from LCM microarrays)
were eligible for subsequent analyses. Preliminary tests
by Anova mixed model showed a prominent effect of
the relative distance of the samples (A, B, C, D, and E)
from the center of the tumor, whereas the direction ofsamples (N, S, E and W, relative to the center of the
tumor) had no effect on gene expression. Thus, data
from samples obtained in the 4 directions of the same
liver area were averaged to increase the power of subse-
quent statistical analyses. To identify genes that were
differentially expressed among the five liver areas, the
areas were globally compared by a multivariate permuta-
tion F-test with a FDR <10% with 80% confidence
level.10 Changes between specific liver areas were then
detected by multiple pairwise t-tests at p = 0.001, using
the subset of genes previously identified by the F-test. A
second series of tests were performed to investigate the
gene expression profile of microdissected hepatocytes by
comparing microarray data of malignant and non-
malignant cells isolated by LCM using a t-test with a
FDR <10%. A parallel analysis was done to compare
microarray data of WLT samples obtained from the cen-
ter of the tumor (A) with those obtained from the most
distant non-tumorous tissue (E). Gene expression fold
changes were calculated as the ratio between the geometric
means of tumor area (A) and non-tumorous tissue area (E),
or malignant and non-malignant microdissected hepato-
cytes. Fold changes < 1 were expressed by the inverse ratio
with a negative sign. Multidimensional scaling and hier-
archical clustering were performed using individual samples
from each patient. Multivariate analysis and heat maps
were done using R software (R Development Core Team,
http://www.r-project.org). Genes were organized into
functional categories according to the Gene Ontology data-
base (http://www.geneontology.org/). Pathway and network
analysis was performed using Ingenuity Pathway Analysis
(IPA) v 9.0 (http://www.ingenuity.com/). The association of
genes to IPA canonical pathways was evaluated as the ratio
between the number of genes present in the data set and
the total number of genes that map to the same pathway.
The Fisher’s exact test was also used to calculate the prob-
ability of such association. The complete microarray dataset
is available at the Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/; accession no.GSE55092).
Results
Characteristics of the patients
We studied 11 patients with HBV-associated HCC.
Demographic, clinical, serological, and pathological fea-
tures, including the grade and size of the tumor, are indi-
cated in Table 1. All but one (91%) were males with a
mean age (±SD) of 59.7 ± 7.7 years. Serum α-fetoprotein
levels were normal in 8 subjects, with a mean (±SD) of
6.1 ± 2.7 ng/mL (normal range, <10.0 ng/mL) and abnor-
mal in 2 patients with values of 20 and 292 ng/mL, re-
spectively. The value was not available in one patient. All
patients were positive for hepatitis B surface antigen
(HBsAg), antibody to hepatitis B core antigen (anti-HBc)
and antibody to hepatitis B e antigen (anti-HBe), and
Table 1 Base-line characteristics of the 11 patients with
HBV-associated HCC
Characteristic
Age, yr 57.7 ± 7.7
Male, No. (%) 10 (90.9)
Alanine aminotransferase, U/La 36.18 ± 17.8
Aspartate aminotransferase, U/Lb 39.09 ± 17.0
Total bilirubin, mg/dL 0.88 ± 0.47
Albumin, g/dLc 3.91 ± 0.57
γ-glutamyltransferase, U/L 93.9 ± 83.56
Prothombin time, INRe 1.13 ± 0.14
Platelet count, per mm3 153,81 ± 93,73
α-fetoprotein, ng/mLd
Normal, No. 8
Abnormal, No. 2
Non-tumorous tissue
Activity Grade 5.75 ± 3.06
Fibrosis Stage 5.1 ± 1.56
F5/F6, No. 9
Tumor Gradef
G2, No. 7
G3, No. 3
G4, No. 1
Tumor size
≥2 cm, No. 4
≥2 and≤ 3 cm, No. 4
>3 cm, No. 3
HBsAg-positive, No. 11
HBeAg-positive, No. 0
Anti-HBc, No. 11
Anti-HBe, No. 11
IgG anti-HDAg positive, No. 1
IgM anti-HDAg, No. 0
Serum HDV RNA positive, No. 0
Anti-HCV positive, No. 1
Serum HCV RNA positive, No. 0
NOTE. Plus-minus values are means ± SD. To convert values for total bilirubin
to micromoles per liter, multiply by 17.1. HBsAg, hepatitis B surface antigen;
HBeAg, hepatitis B e antigen; HDAg, hepatitis delta antigen; HBV, hepatitis B
virus; and HDV, hepatitis D virus.
aNormal range, ≤43 U per liter.
bNormal range, ≤42 U per liter.
cNormal range, ≥3.6 - ≤5.0.
dNormal range, <10.0 ng/mL. Data were not available from one patient.
eNormal range, 0.80-1.20 international normalized ratio (INR).
fTumors were graded using the Edmondson-Steiner criteria.
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to HBsAg (anti-HBs). Patients were receiving antiviral
treatment with nucleos(t)ide analogues prior to surgery.
All, except one, were negative for antibodies to HCV andall were negative for serum HCV RNA. Another patient
was found to be positive for IgG anti-HDV, but repeatedly
negative for IgM anti-HDV and serum HDV RNA,
whereas the remaining patients were negative for all
markers of HDV infection. Of the 11 patients studied, 9
(82%) had underlying cirrhosis. The activity grade and
stage of fibrosis of the surrounding non-tumorous tissue
are reported in Table 1. The tumor size was less or equal
to 3 cm in 8 patients (73%) and larger than 3 cm in the
remaining three patients (Table 1). The grade of tumor
differentiation was found to be G2 in seven patients, G3
in three patients, and G4 in the remaining patient
(Table 1). To define the HCC subtypes of the 11 patients
studied, we used the classification of Yamashita et al. [12]
based on the expression of EPCAM and AFP, tested by im-
munohistochemistry on tumor sections. The results of the
immunohistochemistry were correlated with the expres-
sion levels of EPCAM and AFP at the level of mRNA. We
found that only one of the 11 patients with HBV-
associated HCC in our series was positive for EPCAM but
negative for AFP by immunohistochemistry. This patient
was also the only one to show high EPCAM-mRNA levels
within the tumor both in WLTand LCM. AFP was positive
by immunohistochemistry in only one of the 11 HCC ana-
lyzed, but the level of AFP-mRNA in this patient was simi-
lar to the average level of the other patients. Thus, none of
the 11 patients was positive for both EPCAM and AFP.
Differential gene expression between tumor and non-
tumorous areas
To investigate the molecular changes that occur within a
liver containing HCC, we performed gene expression profil-
ing of multiple liver specimens of the same liver, both within
and outside the tumor, from 11 patients with HBV-
associated HCC. An unsupervised multidimensional scaling
of all 120 specimens obtained from the five areas of HCC-
containing livers disclosed 2 distinct clusters corresponding
to tumor areas (A and B) and non-tumorous areas (C, D
and E) (Figure 1B). To identify the genes that were mostly
responsible for such marked difference between the tumor
and non-tumorous tissue, microarray data of the five differ-
ent areas of HCC-containing livers were compared by a
multivariate permutation F-test [false discovery rate (FDR)
<10%]. The analysis identified 1,486 genes differentially
expressed, with the majority (two-thirds) of genes down-
regulated in the tumor (Additional file 2: Table S1). The F-
test confirmed the overall difference between tumor and
non-tumorous tissue, as all genes that were up-regulated in
the tumor (A and B) areas were down-regulated in all non-
tumorous areas (C, D and E); conversely all genes down-
regulated in the tumor areas were up-regulated in all non-
tumorous areas. A sharp demarcation between tumor and
non-tumorous tissues is also shown by the heat map ob-
tained from WLTgene expression data (Figure 2A).
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expression of HBsAg, HBcAg and HBV DNA in tumor and
non-tumorous areas and in serum
Access to a unique series of liver specimens from 11 pa-
tients with HCC provided us with the opportunity to
study the intrahepatic expression of HBsAg and HBcAg
by confocal immunofluorescence in different areas of theFigure 2 Gene expression profiling and intrahepatic expression of HB
differentially expressed in different areas of livers containing HCC. These data
B tumor periphery; C the perilesional non-tumorous area, outside the tumor m
distant non-tumorous area, the edge of the liver. Data from the center of the
remaining liver areas (from B to E) represent the average of multiple specime
expression of a particular gene (rows) of a particular liver area (columns). The
gene in the corresponding area, relative to its mean level of expression in the
standardized. Up-regulated genes are shown in shades of red, down-regulate
HBsAg immunostaining within and outside the tumor of 11 patients. Data are
and C were available in 8 patients (C). Sections representing different liver are
between the perilesional non-tumorous area (C) and the periphery of the tum
HBsAg positivity was almost diffuse in the most distant non-tumorous area E,
hepatocytes (Inset) were mostly found in areas B and A, respectively (Originalliver, including the center and the periphery of the tumor,
the perilesional area outside the tumor and the most dis-
tant area from the tumor along a single direction. This
analysis allowed us to evaluate the relationship between
gene expression and the intrahepatic expression of HBV.
HBsAg immunostaining was positive in only 6 of 11
tumor tissues, but in all non-tumorous specimens. WhenV antigens in HBV-associated HCC. (A) Heat map of 1,486 genes
were obtained from whole liver tissue. A denotes tumor center;
argin; D a distance of 2-3 cm from the margin of the tumor; E the most
tumor (A) represent individual samples, whereas data from each of the
ns obtained in the 4 directions (N, S, E, and W). Each cell represents the
color in each cell reflects the level of expression of the corresponding
entire set of 120 samples. Ratios were log2-transformed and row-wise
d genes in shades of green. (B) Frequency of positive hepatocytes for
represented as mean SE. Liver samples for HBsAg staining from areas B
as show a significant decrease in number of HBsAg-positive hepatocytes
or margin (B), which further decreased in the center of the tumor (A).
with a gradual decrease in area C, whereas scattered or isolated positive
magnification 20X).
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HBsAg in the different areas of the liver, we observed a
significant drop in the number of positive hepatocytes
from the perilesional non-tumorous area (C) to the per-
iphery of the tumor area (B) (Figure 2B and C), which
mirrored the sharp demarcation observed in the gene
expression profile (Figure 2A). Such a decrease in HBsAg
positivity continued until the center of the tumor, which
was characterized by the lowest levels of HBsAg expres-
sion (Figure 2B). Conversely, no significant differences
were observed in the number of HBsAg-positive hepato-
cytes among the non-tumorous areas. In addition to quan-
titative differences, HBsAg exhibited different expression
patterns in tumor and non-tumorous areas (Figure 3).
Whereas non-tumorous liver tissues were characterized
by a diffuse, scattered or spotty cytoplasmic pattern
(Figure 3A, B and C), tumor tissues showed a scattered
or membranous pattern, the latter being localized on
the plasma membrane uniquely on malignant hepatocytesFigure 3 Patterns of HBsAg expression detected by immunofluoresce
illustrate four representative patterns of HBsAg positivity: cytoplasmic diffus
areas (A) cytoplasmic scattered, found in isolated hepatocytes both in tum
areas of the hepatocyte cytoplasm both in tumoral and non-tumorous area
within the tumoral areas (D). (Original magnification 63×).(Figure 3D). In contrast, HBcAg was negative both in
tumor and non-tumorous tissues, and was positive only in
a few cells in one non-tumorous tissue. Quantification of
HBV DNA in liver by real-time PCR showed low levels of
HBV DNA, without differences between tumor and non-
tumorous areas (Figure 4). These findings were consistent
with the low levels of HBV DNA detected in serum
(Figure 4).
Genes differentially expressed in malignant versus non-
malignant hepatocytes (LCM) and in tumor versus non-
tumorous tissue (WLT)
To identify genes that were differentially expressed in
malignant hepatocytes, a multivariate permutation t-test
with a FDR <10% was performed between microdis-
sected malignant hepatocytes isolated from the central
area of the tumor (A) and microdissected hepatocytes
isolated from the most peripheral non-tumorous area
(E) by LCM. This analysis identified a total of 1,204nce in the liver of patients with HBV-associated HCC. The images
e, extended to vast areas of the liver section, found in non-tumorous
oral and non-tumorous areas (B) cytoplasmic spotty, found in limited
s (C) membranous, limited to the plasma membrane of hepatocytes
Figure 4 HBV DNA levels in liver and serum of patients with HBV-associated HCC. (A) HBV DNA levels in different areas of the liver, within
the center (A) and the periphery of the tumor (B) and progressively distal to the tumor (C and E), as measured by real-time PCR in 11 patients with
HBV-associated HCC. (B) HBV DNA levels in serum of patients with HBV-associated HCC. Quantities are expressed as Log10 IU/ng (liver) or Log10 IU/mL
(serum) as compared to an international HBV DNA standard. The levels of HBV DNA in the different areas of the liver and in serum are shown
as median ± interquartile range. Liver samples for HBV DNA quantification from areas B and C were available in only 8 patients.
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found to be up-regulated and 613 (51%) down-regulated
(Figure 5A and Additional file 3: Table S2). The same
t-test was then applied to identify genes differentially
expressed at the tissue level (WLT) by comparing the
center of the tumor area (A) with the most distant
non-tumorous area (E). Statistical analysis identified
996 genes differentially expressed in the tumor tissue,
with 281 (28%) genes up-regulated and 715 (72%) down-
regulated (Figure 5A and Additional file 4: Table S3). The
marked difference between the percentages of up- and
down-regulated genes detected by LCM and WLT (49/51%
vs 28/72%, respectively) was statistically significant
(p < 0.0001 by Yates’ chi-square). This led us to compare
the sets of genes in order to identify: 1) genes differentially
expressed both in LCM and WLT samples; 2) genes differ-
entially expressed only in WLT; and 3) genes differentially
expressed only in LCM samples (Figure 5B).
Genes differentially expressed both in malignant
hepatocytes and tumor tissue (LCM-WLT-common genes)
Microdissected malignant hepatocytes and whole tumor
tissue shared 736 differentially expressed genes (Figure 5B),
accounting for 61% of LCM genes and 74% of WLT genes
(Additional file 5: Table S4). Bivariate analyses of fold
changes showed a close correlation (r = 0.98) and an almost
unitary slope (b = 0.95), which attested to a consistent
agreement of gene expressions observed in malignant hepa-
tocytes and in tumor tissue (Figure 5C). Among the 736
genes in common, 251 (34%) were up-regulated, whereas
the vast majority were down-regulated (485, 66%). The high
prevalence of down-regulated genes was also reflected by
the analysis of canonical pathways (Figure 6A), which
showed an extensive down-regulation of pathways involvedin the metabolism and degradation of various substrates
(bupropion, acetone, nicotine, melatonin, histidine and
methylglyoxal), activation of PXR/RXR and PPARα/RXRα
nuclear receptors (NR), estrogen biosynthesis, complement
system and fatty acid β-oxidation I. Consistent with down-
regulation of the metabolism-related canonical pathways,
the most represented down-regulated genes were members
of the cytochrome family (CYP2E1, CYP2C9, CYP2A13,
CYP2A6, CYP2A7, CYP3A4, CYP3A5, CYP3A7, CYP1A2,
CYP2B6, CYP2C8, CYP2C19, CYP4A11, CYP4A22) and
genes involved in the metabolism of lipids and hormones
(AKR1D1, ESR1, HMGCS2, LIPC, ABCG5, CETP, PPAP2B,
RDH16, SLC27A2, LCAT, APOA5, ACAA2), carbohydrates
(GYS2, PCK1, FBP1, G6PC, ALDOB), and amino acids
(HAO2, HAL, ASPA, IDO2) (Additional file 5: Table S4).
Also, several genes related to hepatic synthesis, including
complement system and inflammation (C9, FCN3, FCN2,
CXCL14), as well as immune response genes (CLEC1B,
CLEC4G, CLEC4M) were down-regulated. Within NR-
associated canonical pathways, the key transcriptional
regulators PPARGC-1α/ PGC-1α (peroxisome proliferator-
activated receptor gamma coactivator-1 alpha) and FOXO1
(forkhead box O1) were down-regulated. Moreover, most
of down-regulated metabolism-related genes were down-
stream of NRs, thus confirming the major regulatory role of
NRs in HBV-associated HCC. Consistent with increased
cell growth, several negative regulators of cell proliferation
(GADD45A, GADD45B, GADD45G) were down-regulated
(Additional file 5: Table S4). Another gene that was consid-
erably down-regulated within the tumor was sodium
dependent taurocolic cotransporting polypeptide (NTCP/
SLC10A1), which was recently identified as a receptor for
human hepatitis B virus [22]. Among up-regulated genes,
the most represented were those involved in cell cycle and
Figure 5 Differentially expressed genes in whole liver tissue (WLT) and laser capture microdissected hepatocytes (LCM). (A) The pie
diagrams show the percentage of the differentially expressed genes in WLT (n = 996) and LCM (n -= 1,204) obtained by a multivariate permutation
t-test with a FDR < 10%. In both techniques the two sets of genes were obtained by comparing the center of the tumor with the most distant
non-tumorous area. Up-regulated genes are depicted in red, whereas down-regulated genes are in green. (B) Venn diagram showing the common
and unique genes among the sets of genes detected by t-test (FDR < 10%) in WLT and LCM samples. (C) Correlation of log-transformed fold changes
of the 736 common genes identified by LCM and WLT. LCM fold changes were calculated as the ratio between gene expression of malignant and
non-malignant hepatocytes. WLT fold changes were calculated as the ratio between gene expression of tumor and non-tumorous tissue areas (A and
E, respectively). Red and green points represent up-regulated and down-regulated genes, respectively.
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CDK1, ECT2, CCNB1, NDC80, PRC1, NEK2, CENPF)
(Additional file 5: Table S4).
Genes differentially expressed in tumor tissue but not in
microdissected malignant hepatocytes (WLT-unique genes)
The set of genes differentially expressed in tumor tissue
but not in microdissected malignant hepatocytes com-
prised 260 genes, the majority of which (88.5%) were
down-regulated (Figure 5B and Additional file 6: Table S5).
This was consistent with the analysis of the canonicalpathways, which showed a dramatic down-regulation of
pathways involved in amino acid biosynthesis and degrad-
ation, activation of LXR/RXR NR, extrinsic and intrinsic
prothrombin activation pathway, coagulation system, and
acute phase response signaling. In line with these findings,
there was an overriding enrichment of metabolism-related
genes (ADH1A, HPGD, HSD17B2, BBOX1, AGXT2L1)
followed by genes involved in detoxification (AGXT), in-
flammation (C7, HPGD, HRG, HPX, IL13RA2, PTGS2)
and immune response (IGHM and IGL@) (Figure 6B).
Only a minority of genes were up-regulated (11.5%), and
Figure 6 Top-scored canonical pathways of the three gene subsets obtained from the cross analysis comparing WLT (n = 996) and
LCM (n = 1,204) gene lists: (A) LCM-WLT-common genes (n = 736); (B) WLT-unique genes (n = 260); (C) LCM-unique genes (n = 468). The
top-scored canonical pathways of LCM-WLT-common and WLT-unique genes show a striking majority of down-regulated pathways involved in
metabolic processes (A and B). In contrast, the LCM-unique genes (C) are characterized by a predominance of up-regulated pathways involving
cell remodeling and cell motility. Expression of actin/cytoskeleton-, integrins-, and adherens junctions-related pathways suggests cell remodeling
activity, whereas Rac- and Rho-associated pathways are indicative of increased cell motility of malignant hepatocytes. Columns (left axis) represent
the percentage ratio of the number of genes in a given pathway divided by the total number of genes that make up that pathway. Green and
red columns indicate down- and up-regulated genes, respectively. Blue points (right axis) display the -log of p-value calculated by Fisher’s exact
test right-tailed. (Ingenuity Pathway Analysis, www.ingenuity.com). For each dataset, pathways are ordered from the most significant p-values.
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most up-regulated (SFN andMKI67).
Genes differentially expressed in microdissected malignant
hepatocytes but not in tumor tissue (LCM-unique genes)
Cross-comparison of LCM and WLT data identified 468
genes differentially expressed by microdissected malignant
hepatocytes but not in tumor tissue. Unlike the results
obtained with WLT, we observed a predominance of
up-regulated genes (73%) (Figure 5B). Moreover, the
top-scored pathways were not associated with metabolism
but rather with signal transduction cascades mediated
chiefly by integrins and cadherins (integrin signaling, adhe-
rens junction remodeling and signaling, actin nucleation by
ARP-WASP complex and Rac signaling) (Figure 6C and
Additional file 7: Table S6). These pathways control a range
of cell activities such as cell adhesion, motility, contractility
and proliferation by means of cytoskeletal interactions and
rearrangements, as well as activation of transcription fac-
tors. However, these pathways included only 10% (45out of 468) LCM-unique genes. On the other hand, the
analysis of single gene functions was more specifically
related to the nature of malignant hepatocytes, with
more than 50% of the 468 LCM-unique genes associ-
ated with cancer, 29% with cell proliferation, 22% with
apoptosis and 12% with cell survival. Importantly,
among the most up-regulated genes (i.e., genes with
fold changes > 4) four were cancer testis antigen (CTA)
genes (MAGEA3, NUF2, CEP55 and TTK) (Additional
file 7: Table S6). Expression of the 4 CTA genes was
also tested by real-time PCR. Interestingly, the gene ex-
pression profiles of these 4 genes were very similar
when two independent methods were used, showing a
good concordance between signal intensities measured
by gene expression profiling and gene expression mea-
sured by real-time PCR (Additional file 8: Figure S2
and Additional file 9: Figure S3). Recently, Nault et al
[23], reported a 5-gene score in HCC, comprising HN1,
RAN, RAMP3, KRT19, and TAF9, which was associated
with patient survival after liver resection. We have analyzed
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were differently expressed in WLT and LCM. Interestingly,
we found that only 2 out of the 5 genes (HN1 and RAN)
were differentially expressed in our cohort of patients but
only by LCM, suggesting that these genes are specifically
expressed by malignant hepatocytes. The lack of informa-
tion on the long-term clinical outcome and the limited
number of patients included in this study did not allow us
to assess a statistical correlation between gene expression
and survival.
Discussion
Our comparative analysis of multiple liver specimens sam-
pled at various distances from the center of the tumor
allowed us to demonstrate that the liver containing HBV-
associated HCC is characterized by a sharp change in gene
expression at the immediate perilesional area, within milli-
meters of the tumor margin. Moreover, we documented
that this change is highly specific, as all genes down-
regulated within the tumor were up-regulated in all
non-tumorous liver areas and, conversely, all genes up-
regulated in the tumor were down-regulated in all non-
tumorous areas.
To the best of our knowledge, this is the first study
that integrated gene expression profiling of whole liver
tissue with that of microdissected hepatocytes from the
same cohort of patients with HBV-associated HCC. Ac-
cruing evidence has documented the importance of the
LCM technique to study isolated cell populations in tu-
mors that arise in histologically heterogeneous tissues
[24]. The comparison of WLT and LCM data made it
possible to distinguish three subsets of genes: genes de-
tected in both WLT and LCM samples, genes detected
only in LCM samples, and genes detected only in WLT
samples. Interestingly, genes detected in both WLT and
LCM samples showed comparable fold changes and the
vast majority were down-regulated like most of WLT-
unique genes. Conversely, most LCM-unique genes were
up-regulated, indicating that malignant hepatocytes and
whole tumor tissue diverge not only in the nature of
genes differentially expressed but also in the overall dir-
ection of the change. Such a discrepancy underlines the
importance of LCM to collect specific information on
the gene regulation of malignant hepatocytes.
Among genes detected by both WLT and LCM samples,
an overwhelming number of genes were involved in the
metabolism of lipids and fatty acids, glucose, amino acids
and drugs and were down-regulated. In agreement with
our observations, previous studies showed down-regulation
of metabolism-related genes in HBV-related HCC [25], a
feature that is preferentially linked to HBV- rather than to
HCV-associated HCC [26,27]. The reasons for this dra-
matic down-regulation of metabolism-associated genes are
presently unknown, although some studies have suggestedthat this phenomenon is part of the de-differentiation pro-
gram of liver tumor cells, which is particularly evident in
HCC associated with HBV infection [28]. Consistent with
this hypothesis, Nagata et al. [29] found a remarkable
down-regulation of cytochrome-associated genes in fetal
human liver compared to adult liver, and explained this
finding with the absence of hepatocyte-specific function in
fetal livers.
Two of the most overexpressed genes in HBV-
associated HCC, found both by LCM and WLT, that may
be of particular interest are AKR1B10 and IGF2BP3.
AKR1B10 has recently been associated with several tu-
mors including, but not limited to, pancreatic carcinoma
[30], breast cancer [31], and papillary renal carcinoma
[32]. However, studies in HCC are limited [33]. Although
its function is still largely unknown, AKR1B10 was shown
to deplete cells of retinoic acid, which controls cell prolif-
eration [34]. In support of a possible role of retinoic acid
depletion, we also detected down-regulation of RDH16,
the key enzyme responsible for retinoic acid synthesis.
Regarding IGF2BP3, whose function is even less well
established, its depletion has been correlated with a de-
crease in cell motility, invasion and transendothelial mi-
gration [35]. In a recent study published by our group
[36], AKR1B10 and IGF2BP3 were found to be highly up-
regulated in the liver of patients with HBV-associated
acute liver failure and evidence of liver regeneration,
emphasizing the need to further dissect the relationship
between liver regeneration and liver cancer.
An important finding, which further highlights the
value of LCM, is the up-regulation of four CTA genes
(MAGEA3, NUF2, CEP55, and TTK) that we detected
in microdissected malignant hepatocytes, and confirmed
by real-time PCR. MAGEA3, one of the first CTAs asso-
ciated with HCC, is a member of the MAGE gene family
and a candidate for specific HCC immunotherapy [37].
It has been proposed that MAGEA3 may enhance the
ubiquitin ligase activity of TRIM28 and stimulate p53/
TP53 ubiquitination by TRIM28 [38]. The other three
CTAs are directly involved, at various levels, in the mi-
totic machinery. CEP55 has previously been associated
with HCC [39], whereas, to our knowledge, NUF2 and
TTK are novel HCC-associated CTAs. Members of the
CTA family have been suggested as potential targets for
cancer immunotherapy because, unlike most auto-antigens,
they are highly immunogenic, even in autologous cancer-
bearing patients.
One of the major goals of our study was to investigate
the relationship between gene expression and viral bio-
markers in the liver. The sharp change in gene expression
that we documented between the perilesional area and the
periphery of the tumor was mirrored by a significant de-
crease in HBsAg expression. Conversely, the levels of
intrahepatic HBV replication were uniformly low in all the
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was not detectable in any liver specimens with the excep-
tion of a single non-tumorous area from a single patient.
Although the low levels of HBV replication may be ex-
plained by the fact that these patients were all anti-HBe
positive and under antiviral therapy with nucleos(t)ide
analogues prior to surgery, the dramatic and significant
decrease in HBsAg expression within the tumor cannot
be explained by antiviral therapy, because nucleos(t)ide
analogues have no direct effect on transcription and
translation of HBsAg, which was not suppressed in the
tumor-surrounding tissue. The reasons for the dramatic
decrease of HBsAg within the tumor remain to be fully
elucidated. Previous reports have found a lower expres-
sion of HBsAg in HCC as compared with matched
non-tumorous tissues [40,41]. One of the reasons pro-
posed to explain this observation is an increased rate of
integration of HBV DNA into the host genome inside
the tumor [40,42,43]. However, integration of HBV has
also been reported in non-malignant hepatocytes
[40,42,43]. In a recent extensive genome-wide study,
HBV integration was reported in 86% of HCC and in
31% of the surrounding non-tumorous tissue [44].
Although a role for HBV integration in our cohort of
patients cannot be excluded, one of the most interesting
findings in our study was the down-regulation within
the tumor of canonical pathways that are part of the nu-
clear receptor (NR)-associated network. This network is
critically involved not only in the metabolic functions of
the liver but also in the life cycle of HBV, acting as es-
sential transcription factors for viral gene expression
[45,46]. Most notably, we observed down-regulation of
PPARγ coactivator-1 alpha (PGC-1α), a key transcrip-
tional co-activator that acts as a master switcher for a
large number of nuclear receptors [46]. PGC-1α serves
critical functions in the control of cellular energy meta-
bolic pathways [47]. In the liver, it is a key regulator of
gluconeogenesis and fatty acid oxidative metabolism,
and coordinates adaptation to metabolic alterations.
Shlomai et al. [48], demonstrated in a mouse model that
starvation, by turning on the gluconeogenic program,
robustly induces HBV gene expression through the in-
duction of PGC-1α, which serves as a co-activator of
HBV transcription. The importance of PGC-1α in the
HBV life cycle is further highlighted by the strong inhib-
ition of HBV expression observed upon degradation of
PGC-1α using the natural phenolic compound curcu-
min [49]. In addition to NRs, an important non-NR
partner of PGC-1α, FOXO1, was found to be down-
regulated in tumor tissue. FOXO1 is a central mediator
of glucose metabolism in the liver that was shown to
bind HBV and activate its transcription [50]. Thus,
down-regulation of these genes may contribute to the
sudden and significant decrease of HBsAg expressionthat we documented in the tumor. Through the exploit-
ation of several liver-specific transcription factors and
coactivators that regulate vital metabolic functions,
HBV has acquired the ability to specifically replicate in
liver tissue, reducing the risk of development of host
cell resistance and leading to the definition of HBV as a
“metabolovirus” [51]. However, our data documented
down-regulation of essential hepatic metabolism genes,
including PGC-1α and FOXO1, suggesting that the ma-
lignant hepatocyte has developed an autonomous meta-
bolic regulation. Given the fact that PGC-1α and
FOXO1 are essential coactivators of HBV transcription,
we hypothesize that down-regulation of these genes
may contribute to the sudden and significant decrease
of HBsAg expression that we documented in the tumor.
Another possibility that we cannot rule out is whether
the reduced expression of HBsAg may be related to the
increased proliferation rate of tumor cells.
In conclusion, microarray analysis of multiple areas of
livers with HBV-associated HCC provided evidence for a
remarkable change of gene expression in the perilesional
area, within millimeters of the tumor margin. This sud-
den change is paralleled by a sharp decrease in HBsAg
expression. The combined application of WLT and LCM
techniques validated most of the gene expression
changes associated with the tumor. Moreover, LCM
allowed us to identify a series of genes not found in
whole liver tissue (WLT) that may play a role in HCC,
adding a new tool for dissecting pathogenesis and dis-
covering new cancer markers.Additional files
Additional file 1: Figure S1. Representative images of LCM performed
on tumor and non-tumor liver tissue from a patient with HBV-associated
HCC. Panels A and E show the H&E stained tissues on cover-slipped glass
slides, which were evaluated by a trained pathologist prior to dissection by
LCM. Panels B and F show the H&E stained tissues on the PEN membrane
as described in Materials and Methods; the diffraction due to the absence of
a cover slip results in the various shades of brown. Panels C and G show the
selected areas before performing LCM. Panels D and H show the remaining
tissue after LCM. All images are at 2× magnification.
Additional file 2: Table S1. Genes Differentially Expressed among the
Five Liver Areas.
Additional file 3: Table S2. Genes Differentially Expressed between
Microdissected Malignant Hepatocytes and Non-Malignant Hepatocytes.
Additional file 4: Table S3. Genes Differentially Expressed Between
Malignant and Non-Malignant Liver Tissue.
Additional file 5: Table S4. Differentially Expressed Genes in Common
between Whole Liver Tissue (WLT) and Microdissected Hepatocytes
(LCM).
Additional file 6: Table S5. Differentially Expressed Genes Unique to
Whole Liver Tissue.
Additional file 7: Table S6. Differentially Expressed Genes Unique to
Microdissected Hepatocytes.
Additional file 8: Figure S2. Expression levels of four cancer testis antigen
(CTA) genes (MAGEA3, CEP55, TTK and NUF2) of malignant hepatocytes (red
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http://www.translational-medicine.com/content/12/1/230bars) and non-malignant hepatocytes (blue bars), isolated by LCM from 10
HCC patients (numbered 1 to 10). All four CTA genes were up-regulated in
malignant hepatocytes, with fold changes > 4. However, as shown by the plot,
the expression was higher in some patients (leftmost cases) than in others
(rightmost cases).
Additional file 9: Figure S3. Expression of four CTA genes (MAGEA3,
CEP55, TTK and NUF2) in tumor and non-tumorous liver tissue of 10 HCC
patients (numbered 1 to 10) evaluated by RT-qPCR. Data are represented
by –ΔΔCt (red bars), where ΔΔCt = (CtTarget - CtGAPDH )Tumor - (CtTarget -
CtGAPDH)Non-tumor. Results are mean ± standard error.
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